Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2014-03-25 Report Publication Anno…
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Annual Report 2013
Report Publication Announcement Classification · 98% confidence The document explicitly states 'PCI Biotech: Annual Report 2013' in the title and body. It mentions that the Board of Directors has approved the Annual Report for 2013 and that it will be presented to the general assembly. Although it mentions the report is attached, the primary subject matter is the official Annual Report itself, which aligns best with the '10-K' definition (Official yearly report covering company activity and full financial performance), even if the company is not US-listed and might use a local equivalent structure. Given the explicit mention of 'Annual Report', 10-K is the closest standard classification for a full annual filing. However, since the text is very short (483 chars) and states the report is 'attached' and will be presented at the AGM, it strongly suggests this specific document is the *announcement* of the report's availability rather than the report itself. This points towards RPA (Report Publication Announcement) or RNS (Regulatory Filings). Since the document is specifically announcing the publication of the Annual Report, RPA is the most precise fit based on Rule 2 (The 'MENU VS MEAL' Rule).
2014-03-25 English
PCI Biotech: Årsrapport 2013
Annual Report Classification · 100% confidence The document is titled 'Årsrapport 2014' (Annual Report 2014) and 'Årsberetning 2013' (Board of Directors' Report 2013) for PCI Biotech Holding ASA. It provides a comprehensive overview of the company's technology, clinical trials (ENHANCE study), market opportunities, strategy, and organizational structure. Given the length and the nature of the content (a full annual report), it is classified as an Annual Report. FY 2013
2014-03-25 Norwegian
PCI Biotech: Årsrapport 2013
Report Publication Announcement Classification · 98% confidence The document is titled 'PCI Biotech: Årsrapport 2013' (Annual Report 2013). However, the text is very short (459 characters) and explicitly states that the 'Årsrapport 2013 for PCI Biotech Holding ASA er vedlagt' (Annual Report 2013 for PCI Biotech Holding ASA is attached). According to the 'MENU VS MEAL' rule, a short announcement stating a report is attached should be classified as a Report Publication Announcement (RPA), not the full Annual Report (10-K). The document announces the approval of the annual report and its presentation at the general meeting, confirming it is an announcement about the report's availability.
2014-03-25 Norwegian
PCI Biotech: Resultatrapport for 4.kvartal 2013 og foreløpig resultat 2013
Earnings Release Classification · 99% confidence The document is titled "PCI Biotech Holding ASA - Rapport for fjerde kvartal 2013 og foreløpig resultat for året 2013" (Report for the fourth quarter 2013 and preliminary result for the year 2013). It contains detailed operational updates (clinical trials, R&D progress, management changes) and a comprehensive summary of financial results for Q4 2013 and the full year 2013, including a detailed consolidated income statement table. This structure, covering a full fiscal year and a specific quarter with detailed financial figures, strongly indicates a comprehensive periodic report. Since it covers a period shorter than a full year (Q4 and FY), it fits the definition of an Interim/Quarterly Report (IR) rather than the full Annual Report (10-K). The presence of detailed financial tables and operational review confirms it is the report itself, not just an announcement of the report (RPA). Q4 2013
2014-02-25 Norwegian
PCI Biotech: Resultatrapport for 4.kvartal 2013 og foreløpig resultat 2013
Investor Presentation Classification · 98% confidence The document is titled "Fourth Quarter and Preliminary Full Year 2013 Results" and contains detailed highlights of clinical study progress (Phase II and Phase I/II studies), preclinical proof of principle, patent filings, and business development activities. It is structured as a presentation, including slides detailing the PCI technology platform, specific cancer treatments (Head & Neck, Bile Duct), and future forecasts. This content strongly aligns with the materials presented during an earnings announcement or an investor update detailing recent performance and pipeline progress, rather than a formal regulatory filing like a 10-K or a standalone Audit Report. Since it covers quarterly and preliminary full-year results and is presented in a presentation format, it is best classified as an Investor Presentation (IP) or potentially an Earnings Release (ER) if it were the initial summary. Given the depth of clinical and technology detail, Investor Presentation (IP) is the most appropriate fit, as it serves to inform investors about operational and scientific milestones following the period end.
2014-02-25 Norwegian
PCI Biotech: Fourth quarter 2013 and preliminary 2013 results
Investor Presentation Classification · 98% confidence The document is titled "Fourth Quarter and Preliminary Full Year 2013 Results" and contains detailed highlights of clinical study progress (Phase II and Phase I/II studies), preclinical proof of principle, patent filings, and business development activities. It is structured as a presentation, including slides detailing the PCI technology platform, specific cancer treatments (Head & Neck, Bile Duct), and future forecasts. This content strongly aligns with the materials presented during an earnings announcement or an investor update detailing recent performance and pipeline progress, rather than a formal regulatory filing like a 10-K or a standalone Audit Report. Since it covers quarterly and preliminary full-year results and is presented in a presentation format, it is best classified as an Investor Presentation (IP) or potentially an Earnings Release (ER) if it were the initial summary. Given the depth of clinical and technology detail, Investor Presentation (IP) is the most appropriate fit, as it serves to inform investors about operational and scientific milestones following the period end.
2014-02-25 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.